Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 9;10(1):62.
doi: 10.1186/s13601-020-00342-x.

Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

A Bédard  1   2   3 , X Basagaña  1   2   3 , J M Anto  1   2   3   4 , J Garcia-Aymerich  1   2   3 , P Devillier  5 , S Arnavielhe  6 , A Bedbrook  7 , G L Onorato  7 , W Czarlewski  8 , R Murray  9   10 , R Almeida  11 , J A Fonseca  11   12 , J Correia da Sousa  13   14 , E Costa  15   16 , M Morais-Almeida  17 , A Todo-Bom  18 , L Cecchi  19 , G De Feo  20 , M Illario  21 , E Menditto  22 , R Monti  23 , C Stellato  24 , M T Ventura  25 , I Annesi-Maesano  25 , I Bosse  26 , J F Fontaine  27 , N Pham-Thi  28 , M Thibaudon  29 , P Schmid-Grendelmeier  30 , F Spertini  31 , N H Chavannes  32 , W J Fokkens  33 , S Reitsma  33 , R Dubakiene  34 , R Emuzyte  35 , V Kvedariene  36 , A Valiulis  37   38 , P Kuna  39 , B Samolinski  40 , L Klimek  41 , R Mösges  42 , O Pfaar  43 , S Shamai  42 , R E Roller-Wirnsberger  44 , P V Tomazic  45 , D Ryan  46 , A Sheikh  47 , T Haahtela  48 , S Toppila-Salmi  48 , E Valovirta  49 , V Cardona  50 , J Mullol  51 , A Valero  52 , M Makris  53 , N G Papadopoulos  54   55 , E P Prokopakis  56 , F Psarros  57 , C Bachert  58   59   60   61 , P W Hellings  62   63 , B Pugin  63 , C Bindslev-Jensen  64 , E Eller  64 , I Kull  65 , E Melén  66 , M Wickman  67 , G De Vries  68 , M van Eerd  68 , I Agache  69 , I J Ansotegui  70 , S Bosnic-Anticevich  71   72 , A A Cruz  73   74 , T Casale  75 , J C Ivancevich  76 , D E Larenas-Linnemann  77 , M Sofiev  78 , D Wallace  79 , S Waserman  80 , A Yorgancioglu  81 , D Laune  6 , J Bousquet  82   83   84   85   86   87 ; MASK study group
Affiliations
Review

Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study

A Bédard et al. Clin Transl Allergy. .

Erratum in

Abstract

Background: The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic rhinitis control, but additive information is needed. A cross-sectional real-world observational study was undertaken in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information including the phenotypic characteristics of the users.

Methods: The Allergy Diary-MASK-air-mobile phone app, freely available via Google Play and App, was used to collect the data of daily visual analogue scales (VASs) for overall allergic symptoms and medication use. Fluticasone Furoate (FF), Mometasone Furoate (MF), Azelastine Fluticasone Proprionate combination (MPAzeFlu) and eight oral H1-antihistamines were studied. Phenotypic characteristics were recorded at entry. The ARIA severity score was derived from entry data. This was an a priori planned analysis.

Results: 9037 users filled in 70,286 days of VAS in 2016, 2017 and 2018. The ARIA severity score was lower outside than during the pollen season. Severity was similar for all treatment groups during the pollen season, and lower in the MPAzeFlu group outside the pollen season. Days with MPAzeFlu had lower VAS levels and a higher frequency of monotherapy than the other treatments during the season. Outside the season, days with MPAzeFlu also had a higher frequency of monotherapy. The number of reported days was significantly higher with MPAzeFlu during and outside the season than with MF, FF or oral H1-antihistamines.

Conclusions: This study shows that the overall efficacy of treatments is similar during and outside the pollen season and indicates that medications are similarly effective during the year.

Keywords: Allergic rhinitis; Anti-histamines; Corticosteroids; ICT; MASK; Mobile health; Treatment.

PubMed Disclaimer

Conflict of interest statement

Dr. Almeida reports grants from ERDF (European Regional Development Fund) through the operation POCI-01-0145-FEDER-029130 (“mINSPIRERS—mHealth para medição e melhoria da adesão à medicação nas doenças respiratórias obstrutivas crónicas—generalização e avaliação de tecnologias de gamificação, suporte por pares e processamento avançado de imagem”) funded by the Programa Operacional Competitividade e Internacionalização—COMPETE2020 and by National Funds through FCT (Fundação para a Ciência e a Tecnologia, during the conduct of the study.Dr. Ansotegui reports personal fees from Hikma, Roxall, Astra Zeneca, Menarini, UCB, Faes Farma, Sanofi, Mundipharma, outside the submitted work.Bachert: Meda, Stallergenes and ALK (speaker). J Bousquet reports personal fees and other from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, outside the submitted work. other from Kyomed. Dr. Bosnic-Anticevich reports personal fees from Teva, Boehringer Ingelheim, Sanofi, GSK, AstraZeneca, outside the submitted work. Dr. Cardona reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermofisher, Stallergenes, outside the submitted work. Dr. Cecchi reports personal fees from Menarini, Malesci, ALK Abellò, Menarini, non-financial support from Mundipharma, outside the submitted work.Dr. Correia-de-Sousa reports other from Boheringer Ingelheim, GSK, AstraZeneca, outside the submitted work. Dr. Cruz reports grants and personal fees from Astrazeneca, grants from GSK, personal fees from Boehringer Ingelheim, CHIESI, NOVARTIS, Eurofarma, MEDA Pharma, Boston Scientific, outside the submitted work. Dr. Devillier reports personal fees and non-financial support from Astra Zeneca, Mylan, Stallergenes Greer, personal fees from ALK Abello, Menarini, GlaxoSmithKline, Sanofi, outside the submitted work. Dr. Haahtela reports personal fees from Mundipharma, Novartis, and Orion Pharma, outside the submitted work. Dr. Eller reports other from Thermofisher Scientific, outside the submitted work. Dr. Fonseca reports personal fees from AstraZeneca, GSK, Novartis, Teva, grants from Mundipharma, outside the submitted work. Dr. Ivancevich reports personal fees from Faes Farma Euro-Farma Argentina, other from Lboratorios Casasco, Sanofi, outside the submitted work. Dr. Fokkens reports grants from Mylan, ALK, Allergy Therapeutics, GSK, Sanofi, Novartis, outside the submitted work. Dr. Klimek reports personal fees from MEDA, Sweden, Boehringer Ingelheim, Germany, grants and personal fees from ALK Abelló, Denmark, Novartis, Switzerland, Allergopharma, Germany, Bionorica, Germany, GSK, Great Britain, Lofarma, Italy, grants from Biomay, Austria, HAL, Netherlands, LETI, Spain, Roxall, Germany Bencard, Great Britain, outside the submitted work. Dr. Kuna reports personal fees from Adamed, Boehringer Ingelheim, AstraZeneca, Chiesi, FAES, Berlin Chemie, Novartis, Polpharma, Allergopharma,outside the submitted work. Dr Kvedariene has received payment for consultancy from GSK and for lectures from StallergensGreer, Berlin-CHemie outside the submitted work. Dr. Larenas Linnemann reports personal fees from Amstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim, Chiesi, outside the submitted work. Dr. Melén reports personal fees from Advisory board reimbursement from Novartis, outside the submitted work. Dr. Ralph Mösges reports personal fees from ALK, allergopharma, Allergy Therapeutics, Hexal, personal fees from Servier, personal fees from Klosterfrau, Stada, UCB, Friulchem, grants from ASIT biotech, Nuvo, Bayer, FAES, GSK, MSD, Johnson&Johnson, Meda, Optima, Ursapharm, BitopAG, Hulka, grants and personal fees from Bencard, grants from Leti, Stallergenes, grants, personal fees and non-financial support from Lofarma, non-financial support from Roxall, from Atmos, from Bionorica, Otonomy, Ferrero, personal fees and non-financial support from Novartis, outside the submitted work. Dr. Papadopoulos reports grants from Gerolymatos, personal fees from Hal Allergy B.V., Novartis Pharma AG, Menarini, Hal Allergy B.V., Mylan, outside the submitted work. Dr. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., grants from Glaxo Smith Kline, Biomay, Nuvo, Circassia, personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner Indoor Biotechnologies, Astellas Pharma Global, outside the submitted work. Dr. Ryan reports personal fees from Mylan, AZ, AZ, GSK, from Chiesi, BI, grants from Mylan, outside the submitted work.Dr Schmid-Grendelmeier reports honarium and consultancy fees from ALK-Abello, Allergopharma, Bencard, MEDA and Stallergenes Dr. Stelmach reports grants from São Paulo Research Foundation, MSD, grants and personal fees from Novartis, grants, personal fees and non-financial support from AstraZeneca, Chiesi, personal fees and non-financial support from Boheringer Ingelheim, outside the submitted work. Dr. Todo-Bom reports grants and personal fees from Novartis, Mundipharma, GSK Teva Pharma, personal fees from AstraZeneca, grants from Boehringer Ingelheim, Sanofi, Leti, outside the submitted work. Dr. Toppila-Salmi reports other from Biomedical Systems Ltd., Roche Ltd., grants from Erkko Foundation, outside the submitted work. Dr. Waserman reports other from CSL Behring Shire, AstraZeneca, Teva, Meda, other from Merck, GSK, Novartis, Pediapharm, Aralez Sanofi, Stallergenes, outside the submitted work.

Figures

Fig. 1
Fig. 1
Flow chart of the study population
Fig. 2
Fig. 2
Proportion of INCS treatment groups on all days during and outside the pollen season
See this image and copyright information in PMC

References

    1. Bousquet J, Arnavielhe S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018;8:45. doi: 10.1186/s13601-018-0227-6. - DOI - PMC - PubMed
    1. Bousquet J, Anto JM, Annesi-Maesano I, Dedeu T, Dupas E, Pepin JL, et al. POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. Clin Transl Allergy. 2018;8:36. doi: 10.1186/s13601-018-0221-z. - DOI - PMC - PubMed
    1. Bousquet J, Bedbrook A, Czarlewski W, Onorato GL, Arnavielhe S, Laune D, et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy. 2019;9:16. doi: 10.1186/s13601-019-0252-0. - DOI - PMC - PubMed
    1. Bedard A, Basagana X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin Immunol. 2019;144(1):135-43 e6. - PubMed
    1. Nagarajan N, Jalal D. Resistant Hypertension: Diagnosis and Management. Adv Chronic Kidney Dis. 2019;26(2):99–109. doi: 10.1053/j.ackd.2019.03.002. - DOI - PubMed